JA2-WP5 EUnetHTA Joint Action 2 (2012-15)
2015 - PDF



The purpose of the assessment is to evaluate Ramucirumab (Cyramza®) in combination with Paclitaxel for the treatment of gastric cancer.

Final version of the assessment was published in March 2015

Below is the documentation provided by the Joint Assessment authoring team: